Treatment of central serous chorioretinopathy with beta-blocker
metipranolol

J 2015

Treatment of central serous chorioretinopathy with beta-blocker metipranolol

CHRAPEK, Oldřich; Barbora JIRKOVA; Vít KANDRNAL; Jiri REHAK; Martin SIN et al.

Základní údaje

Originální název

Treatment of central serous chorioretinopathy with beta-blocker metipranolol

Autoři

CHRAPEK, Oldřich; Barbora JIRKOVA; Vít KANDRNAL; Jiri REHAK a Martin SIN

Vydání

Biomedical Papers, Olomouc, Palacky University, 2015, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.924

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083531

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

betablocker; central serous chorioretinopathy; metipranolol

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 11. 2019 12:36, Mgr. Tereza Miškechová

Anotace

V originále

Aim. The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC). Methods. A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium. Results. There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341). Conclusions. In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.

Citovat

CHRAPEK, Oldřich; Barbora JIRKOVA; Vít KANDRNAL; Jiri REHAK a Martin SIN. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomedical Papers. Olomouc: Palacky University, 2015, roč. 159, č. 1, s. 120-123. ISSN 1213-8118. Dostupné z: https://doi.org/10.5507/bp.2013.015.

@article{1307984,
   author = {Chrapek, Oldřich and Jirkova, Barbora and Kandrnal, Vít and Rehak, Jiri and Sin, Martin},
   article_location = {Olomouc},
   article_number = {1},
   doi = {https://doi.org/10.5507/bp.2013.015},
   keywords = {betablocker; central serous chorioretinopathy; metipranolol},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers},
   title = {Treatment of central serous chorioretinopathy with beta-blocker metipranolol},
   volume = {159},
   year = {2015}
}

TY  - JOUR
ID  - 1307984
AU  - Chrapek, Oldřich - Jirkova, Barbora - Kandrnal, Vít - Rehak, Jiri - Sin, Martin
PY  - 2015
TI  - Treatment of central serous chorioretinopathy with beta-blocker metipranolol
JF  - Biomedical Papers
VL  - 159
IS  - 1
SP  - 120-123
EP  - 120-123
PB  - Palacky University
SN  - 12138118
KW  - betablocker
KW  - central serous chorioretinopathy
KW  - metipranolol
N2  - Aim. The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC). Methods. A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium. Results. There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341). Conclusions. In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.
ER  -

CHRAPEK, Oldřich; Barbora JIRKOVA; Vít KANDRNAL; Jiri REHAK a Martin SIN. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. \textit{Biomedical Papers}. Olomouc: Palacky University, 2015, roč.~159, č.~1, s.~120-123. ISSN~1213-8118. Dostupné z: https://doi.org/10.5507/bp.2013.015.

Přehled o publikaci